Who are CTC-501's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): HP-802-247, MB-102 DMID, [68Ga]Ga-PentixaFor, Open single period A140, mini CYVE, without 3 maintenance courses, CHS-1420.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ctc-501.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CTC-501 — Competitive Intelligence Brief

CTC-501 (CTC-501) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD47-SIRPα inhibitor. Area: Oncology.

phase 2 CD47-SIRPα inhibitor CD47 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CTC-501 (CTC-501) — Chase Therapeutics Corporation. CTC-501 is a CD47-SIRPα inhibitor, which works by blocking the interaction between CD47 and SIRPα on the surface of immune cells, thereby enhancing the immune system's ability to recognize and destroy cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CTC-501 TARGET	CTC-501	Chase Therapeutics Corporation	phase 2	CD47-SIRPα inhibitor	CD47
HP-802-247	HP-802-247	Healthpoint	phase 3	CD47 antibody	CD47
MB-102 DMID	MB-102 DMID	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	phase 3	monoclonal antibody	CD47
[68Ga]Ga-PentixaFor	[68Ga]Ga-PentixaFor	Nantes University Hospital	phase 3	Radiopharmaceutical	CD47
Open single period A140	Open single period A140	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	phase 3	CD47 inhibitor	CD47
mini CYVE, without 3 maintenance courses	mini CYVE, without 3 maintenance courses	Gustave Roussy, Cancer Campus, Grand Paris	phase 3	CD47/SIRPα inhibitor	CD47
CHS-1420	CHS-1420	Coherus Oncology, Inc.	phase 3	Bispecific antibody	CD47 and CD40

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD47-SIRPα inhibitor class)

Chase Therapeutics Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CTC-501 — Competitive Intelligence Brief. https://druglandscape.com/ci/ctc-501. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab